


U.S.S.N.: Continuation of 08/823,999  
Filed: February 7, 2001  
INFORMATION DISCLOSURE STATEMENT

J1040 U.S. PTO  
09/776533  
02/07/01

**CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.10**

I hereby certify that this INFORMATION DISCLOSURE STATEMENT and any documents referred to as attached therein are being deposited with the United States Postal Service on this date, February 7, 2001, in an envelope as "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10, Mailing Label Number EL 709 418 819 US, addressed to BOX PATENT APPLICATION, Assistant Commissioner for Patents, Washington, D.C. 20231.



Sunny G. Johns

Date: February 7, 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



Applicants: Campbell Rogers, Elazer R. Edelman, and Daniel I. Simon

Serial No.: Continuation of 08/823,999      Art Unit: Not Yet Assigned

Filed: February 7, 2001      Examiner: Not Yet Assigned

For: *MODULATION OF VASCULAR HEALING BY INHIBITION OF LEUKOCYTE  
ADHESION AND FUNCTION*

Assistant Commissioner for Patents  
Washington, D.C. 20231

**INFORMATION DISCLOSURE STATEMENT**

Sir:

Pursuant to 37 C.F.R. §1.56 and 37 C.F.R. §1.97, Applicants submit an Information Disclosure Statement, including seven (7) pages of Form PTO-1449. The documents cited below were cited by or submitted to the Patent Office in Application Serial No. 08/823,999, filed March 25, 1997, to which the present application claims priority. Pursuant to 37 C.F.R. §1.98(d), Applicants are not enclosing copies of these publications. Copies will be provided upon request, however.

This Information Disclosure Statement is being filed under 37 C.F.R. § 1.97(b) prior to a first Office Action on the merits. It is believed that no fee is required with this submission. However, should a fee be required, the Commissioner is hereby authorized to charge any required fees to Deposit Account No. 01-2507.

### U.S. Patents

<u>Number</u>	<u>Issue Date</u>	<u>Patentee</u>	<u>Class/Subclass</u>
4,244,946	01-13-1981	Rivier et al.	424/177
4,305,872	12-15-1981	Johnston et al.	260/112.5 R
4,316,891	02-23-1982	Guillemin et al.	424/177
4,629,784	12-16-1986	Stammer	530/328
4,792,525	12-20-1988	Ruoslahti et al.	435/240.243
4,868,116	09-19-1989	Morgan et al.	435/240.2
4,980,286	12-25-1990	Morgan et al.	435/172.3
5,324,510	06-28-1994	Wegner et al.	424/85.8
5,567,435	10-22-1996	Hubbell et al.	424/426
5,770,198	06-23-1998	Coller et al	424/53.1

### Foreign Documents

<u>Number</u>	<u>Publication Date</u>	<u>Patentee</u>	<u>Country</u>
WO 93/01286	01-21-1993	Massachusetts Institute of Technology	PCT

### Publications

AGRAWAL, et al., "Oligodeoxynucleoside phosphoramidates and phosphorothioates as inhibitors of human immunodeficiency virus," *Proc. Natl. Acad. Sci. USA* 85(19):7079-7083 (1988).

ALBELDA, et al., "Adhesion molecules and inflammatory injury," *FASEB J* 8:504-512 (1994).

ALTIERI, et al., "Oligospecificity of the Cellular Adhesion Receptor MAC-1 Encompasses an Inducible Recognition Specificity for Fibrinogen," *J. Cell Biol.* 107(5):1893-1900 (1988).

ALTIERI, et al., "The Structural Motif Glycine 190-Valine 202 of the Fibrinogen  $\alpha$  Chain Interacts with CD11b/CD18 Integrin ( $\alpha_M\beta_2$ , Mac-1) and Promotes Leukocyte Adhesion," *J. Biol. Chem.* 268(3):1847-1853 (1993).

ANDERSON, et al., "Contributions of the Mac-1 Glycoprotein Family and Adherence-Dependent Granulocyte Functions: Structure-Function Assessments Employing Subunit-Specific Monoclonal Antibodies," *J. Immunol.* 137(1):15-27 (1986).

ASKEW, et al., "Molecular Recognition with Convergent Functional Groups. Synthetic and Structural Studies with a Model Receptor for Nucleic Acid Components," *J. Am. Chem. Soc.* 111(3):1082-1090 (1989).

AULT, et al., "Cross-Reaction of a Rat-Anti-Mouse Phagocyte-Specific Monoclonal Antibody (ANTI-Mac-1) with Human Monocytes and Natural Killer Cells," *J. Immunol.* 126(1):359-364 (1981).

BLUME, et al., "Triple helix formation by purine-rich oligonucleotides targeted to the human dihydrofolate reductase promoter," *Nucl. Acids Res.* 20(7):1777-1784 (1992).

CLACKSON, et al., "Making antibody fragments using phage display libraries," *Nature* 352(6336):624-688 (1991)

COONEY, et al., "Site-Specific Oligonucleotide Binding Represses Transcription of the Human *c-myc* Gene *in Vitro*," *Science* 241:456-459 (1988).

CROOKE, "Progress toward oligonucleotide therapeutics: pharmacodynamic properties," *FASEB J.* 7(6):533-539 (1993).

DAUGHERTY, et al., "Polymerase chain reaction facilitates the cloning, CDR-grafting, and rapid expression of a murine monoclonal antibody directed against the CD18 component of leukocyte integrins," *Nucl. Acids Res.* 19(9):2471-2476 (1991).

DIAMOND, et al., "The I Domain Is a Major Recognition Site on the Leukocyte Integrin Mac-1 (CD11b/CD18) for Four Distinct Adhesion Ligands," *J. Cell Bio.* 120(4):1031-1043 (1993).

DUVAL-VALENTIN, et al., "Specific inhibition of transcription of triple helix-forming oligonucleotides," *Proc. Natl. Acad. Sci. USA* 89(2):504-508 (1992).

EDGINGTON, "How sweet it is: selectin-mediating drugs," *Biotechnology* 10:383-389 (1992).

ELLINGTON, et al., "*In vitro* selection of RNA molecules that bind specific ligands," *Nature* 346(6287):818-822 (1990).

ELLINGTON, et al., "Selected *in vitro* of single-stranded DNA molecules that fold into specific ligand-binding structures," *Nature* 355(6363):850-852 (1992).

FISCHMAN, et al., "A Randomized Comparison of Coronary-Stent Placement and Balloon Angioplasty in the Treatment of Coronary Artery Disease," *N. E. J. Med.* 331(8):496-501 (1994).

GENNETA & MAURO, "Abciximab: a new antiaggregant used in angioplasty," *Annals of Pharmacotherapy* 30:251-257 (1996).

GRIGORIEV, et al., "A Triple Helix-forming Oligonucleotide-Intercalator Conjugate Acts as a Transcriptional Repressor via Inhibition of NF  $\kappa$ B Binding to Interleukin-2 Receptor  $\alpha$ -Regulatory Sequence," *J. Biol. Chem.* 267(5):3389-3395 (1992).

HOLT, et al., "An Oligomer Complementary to *c-myc* mRNA Inhibits Proliferation of HL-60 Promyelocytic Cells and Induces Differentiation," *Mol. Cell. Biol.* 8(2):963-973 (1988).

INOUE, et al., "Expression of Polymorphonuclear Leukocyte Adhesion Molecules and Its Clinical Significance in Patients Treated With Percutaneous Transluminal Coronary Angioplasty," *JACC* 28(5):1127-1133 (1996).

ITAKURA, et al., "Synthesis and Use of Synthetic Oligonucleotides," *Ann. Rev. Biochem.* 53:323-356 (1984).

KABAT, et al., Sequences of Proteins of Immunological Interest, 4th Ed. (U.S. Dept. Health and Human Services, Bethesda, MD 1987) (Title page and Table of Contents only).

LEWIS, et al., "Automated site-directed drug design: the concept of spacer skeletons for primary structure generation," *Proc. R. Soc. Lond.* 236:125-140 and 141-162 (1989).

MAHER, et al., "Inhibition of DNA Binding Proteins by Oligonucleotide-Directed Triple Helix Formation," *Science* 245:725-730 (1989).

McKINLAY, et al., "Rational Design of Antiviral Agents," *Ann. Rev. Pharmacol. Toxicol.* 29: 111-122 (1989).

MERRIFEILD, "Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide," *J. Am. Chem. Soc.* 85:2149-2154 (1963).

MICKELSON, et al., "Leukocyte Activation With Platelet Adhesion After Coronary Angioplasty: A Mechanism for Recurrent Disease?" *JACC* 28(2):345-353 (1996).

MULLIGAN, "The Basic Science of Gene Therapy," *Science* 260:926-932 (1993).

NARANG, et al., "Chemical Synthesis of Deoxyligonucleotides by the Modified Triester Method," Methods Enzymol., Vol. 65, Chapter 61, pp. 610-620 (The Academic Press, New York 1980).

NEUMANN, et al., "Neutrophil and platelet activation at balloon-injured coronary artery plaque in patients undergoing angioplasty," *JACC* 27(4):819-24 (1996).

OFFENSBERGER, et. al., "*In Vivo* inhibition of duck hepatitis B virus replication and gene expression by phosphorothioate modified antisense oligodeoxynucleotides," *EMBO J.* 12(3):1257-1262 (1993).

ORSON, et al., "Oligonucleotide inhibition of IL2R $\alpha$  mRNA transcription by promoter region collinear triplex formation in lymphocytes," *Nucl. Acids Res.* 19(12):3435-3441 (1991).

PEPINE, et al., "A Controlled Trial of Coricocosteroids to Prevent Restenosis After Coronary Angioplasty," *Circulation* 81(6):1753-1761 (1990).

PERRY, et al., "The Use of 3D Modelling Databases for Identifying Structure Activity Relationships," in QSAR: Quantitative Structure-Activity Relationships in Drug Design, (Fauchère, ed.) pp. 189-193 (Alan R. Liss, Inc. 1989).

PIETERSMA, et al., "Late Lumen Loss After Coronary Angioplasty Is Associated With the Activation Status of Circulating Phagocytes Before Treatment," *Circulation* 91(5):1320-1325 (1995).

POSTEL, et al., "Evidence that a triplex-forming oligodeoxyribonucleotide binds to the *c-myc* promoter in HeLa cells, thereby reducing *c-myc* mRNA levels," *Proc. Natl. Acad. Sci. USA* 88(18):8227-8231 (1991).

RICEVUTI, et al., "Role of granulocytes in endothelial injury in coronary heart disease in humans," *Atherosclerosis* 91:1-14 (1991).

RIPKA, "Computers picture the perfect drug," *New Scientist* 1617:54-57 (1988).

ROGERS, et al., "Inhibition of Experimental Neointimal Hyperplasia and Thrombosis Depends on the Type of Vascular Injury and the Site of Drug Administration," *Circulation* 88(3):1215-1221 (1993).

ROGERS, et al., "Monocyte Recruitment and Neointimal Hyperplasia in Rabbits Coupled Inhibitory Effects of Heparin," *Art. Thromb. Vasc. Bio.* 16:1312-1318 (1996).

ROGERS, et al., "Endovascular Stent Design Dictates Experimental Restenosis and Thrombosis," *Circulation* 91(12):2995-3001 (1995).

ROUVINEN, et al., "Computer and Drug Design," *Acta Pharmaceutica Fennica* 97:159-166 (1988).

SARIN, et al., "Inhibition of acquired immunodeficiency syndrome virus by oligodeoxynucleoside methylphosphonates," *Proc. Natl. Acad. Sci. USA* 85(20):7448-7794 (1989).

SERRUYS, et al., "A Comparison of Ballon-Expandable-Stent Implantation with Balloon Angioplasty in Patients with Coronary Artery Disease," *N. E. J. Med.* 331(8):489-495 (1994).

SHAW, et al., "Modified deoxyoligonucleotides stable to exonuclease degradation in serum," *Nucleic Acids Res.* 19(4):747-750 (1991).

SIMON, et al., "7E3 Monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1," *Arteriosclerosis, Thrombosis, and Vascular Biology* 17(3):528-535 (1997).

/ SIMON, et al., "Monoclonal antibody directed against the platelet IIb/IIIa receptor cross-reacts with the leukocyte integrin mac-1 and blocks adhesion to fibrinogen and ICAM-1," *Circulation Abstract No. 0519 (Suppl 1)* 92(8):1-110 (1995).

SZOSTAK, "In Vitro Genetics," *TIBS* 17:89-93 (1992).

WICKSTROM, et al., "Human promyelocytic leukemia HL-60 cell proliferation and *c-myc* protein expression are inhibited by an antisense pentadecadeoxynucleotide targeted against *c-myc* mRNA," *Proc. Natl. Acad. Sci. USA* 85(4):1028-1032 (1988).

YOUNG, et al., "Triple helix formation inhibits transcription elongation *in vitro*," *Proc. Natl. Acad. Sci. USA* 88(22):10023-10026 (1991).

ZAMECNIK, et al., "Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide," *Proc. Natl. Acad. Sci. USA* 75(1):280-284 (1978).

ZAMECNIK, et al., "Inhibition of replication and expression of human T-cell lymphotropic virus type III in cultured cells by exogenous synthetic oligonucleotides complementary to viral RNA," *Proc. Natl. Acad. Sci.*, 83(12):4143-4146 (1986).

ZHU, et al., "Systemic Gene Expression After Intravenous DNA Delivery Into Adult Mice," *Science* 261:209-211 (1993).

**Remarks**

This statement should not be interpreted as a representation that an exhaustive search has been conducted or that no better art exists. Moreover, Applicants invite the Examiner to make an independent evaluation of the cited art to determine its relevance to the subject matter of the present application. Applicants are of the opinion that their claims patentably distinguish over the art referred to herein, either alone or in combination.

Respectfully submitted,



Patrea L. Pabst  
Reg. No. 31,284

Dated: February 7, 2001

ARNALL GOLDEN & GREGORY, LLP  
2800 One Atlantic Center  
1201 W. Peachtree Street  
Atlanta, Georgia 30309-3450  
(404) 873-8794  
(404) 873-8795 (fax)